---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-010358"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:54:30.146689+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eton out-licenses international rights to Increlex to Esteve for €4M upfront

## Summary
- Esteve pays €4M upfront; license runs up to ten years with option to buy international rights for up to €6M.
- Eton supplies Increlex at a fixed transfer price; no change to expected $80M annual revenue run rate exiting 2025.
- Deal lets Eton focus on three rare-disease product launches planned in the U.S. for 2025.
- Eton eliminates need for significant ex-U.S. commercialization infrastructure investment.

## SEC filing metadata
- accession: 0001437749-25-010358
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774925010358/0001437749-25-010358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774925010358/eton20250321_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-010358
- JSON: https://secwatch.observer/filing/0001437749-25-010358.json
- Plain text: https://secwatch.observer/filing/0001437749-25-010358.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.